AlphAIAlphAI — Financial news for AI agents
rttnews.comSEP 181 min read$SILO

Silo Pharma Gets U.S. Patent Allowance For SPC-15 PTSD Treatment

Silo Pharma (SILO) received a U.S. patent allowance for SPC-15, its PTSD treatment. The patent covers compositions and methods for preventing stress-induced behavioral responses. The company's stock closed at $1.72, down 2.27%, and is trading at $1.65 in pre-market.

Original reporting
rttnews.com
Published Sep 18, 2026, 5:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 18, 2026, 6:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefTechnology
Primary signal
$SILO
Bullish
medium confidence
Mentioned
$SILO
Relevance
5/10
AlphAI data visualization · based on rttnews.com
Decision brief

The 30-second read

$SILOBullishLow
01

Why it matters

The patent allowance could enhance the company's valuation and attract partnership interest.

02

Market read

First disclosure of a patent allowance for a micro‑cap biotech, modest trading relevance.

03

What to watch

Potential competition and regulatory hurdles for intranasal PTSD treatments.

Relevance 5/10Novelty 6/10Timing: pre‑market today

Background

Silo Pharma is a developmental‑stage biopharma focused on CNS disorders.

Company-level read

Ticker impact

$SILOBullishMedium confidence
Context

USPTO issued a Notice of Allowance for Silo Pharma's SPC-15 PTSD therapeutic patent.

Expected impact

modest upside potential if clinical data follow through

Evidence & confidence

The allowance is a positive catalyst but the company remains micro‑cap with limited liquidity.

Market effects

Sector

Adds credibility to biotech IP pipelines, may influence peer valuations.

Regional

Minor effect on US biotech sector.

Global

Limited to investors tracking early‑stage psychiatric therapeutics.

Counterpoint

What could challenge this read

Patent allowance may not translate to commercial success without trial data.

Key entities

  • Company
    Silo Pharma, Inc.

    Developer of SPC-15 intranasal PTSD therapeutic.

  • Regulatory Agency
    USPTO

    Issued the Notice of Allowance for the patent.

Read at source← All news

Related articles

JUL 10
$SILOMed

Silo Pharma Sinks on Stock Sale

Silo Pharma (NASDAQ: SILO) said it entered definitive agreements for a private placement at-the-market under NASDAQ rules to issue and sell 619,965 shares, or pre-funded warrants, plus Series A-3 and short-term Series A-4 warrants. Price was $6.452 per share, with $6.21 exercise price. Gross proceeds are about $4 million, up to $7.7 million if warrants are fully exercised.

baystreet.ca2 min
JUL 10
$SILOMedAI 8/10

Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Silo Pharma (Nasdaq: SILO) announced a private placement under Nasdaq at-the-market rules to issue 619,965 shares (or pre-funded warrants) at $6.452 per share, with Series A-3 and short-term Series A-4 warrants exercisable immediately. Gross proceeds are expected at about $4.0M, with up to about $7.7M more if warrants are fully exercised. Proceeds will fund working capital and general corporate purposes.

manilatimes.net4 min
JUL 10
$SILOMedAI 8/10

Silo Pharma, Inc.: Silo Pharma Announces up to $11.7 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Silo Pharma (Nasdaq: SILO) announced a private placement priced at-the-market under Nasdaq rules for 619,965 shares (or pre-funded warrants) plus Series A-3 and short-term Series A-4 warrants to buy up to 619,965 shares each. Price is $6.452 per share, with $6.21 warrant exercise. Gross proceeds are about $4M upfront, up to $7.7M if warrants are fully exercised in cash. Net proceeds for working capital and general corporate purposes.

finanznachrichten.de3 min
JUL 10
$METAHighAI 8/10

CCC Intelligent Solutions, Circle rise premarket; Silo Pharma, Fermi America fall By Investing.com

U.S. stock index futures were mixed premarket on Friday, with S&P 500 futures flat and Nasdaq 100 futures down 0.3% by 08:25 ET. CCC Intelligent Solutions rose 14.5% on a Reuters report it is exploring a sale with Morgan Stanley. Circle gained 7% after OCC approval for a digital currency bank. Meta rose 3.8% on a new AI model. Fermi America fell 14.6% after pricing $375m convertible notes, and Silo Pharma dropped 22% on an up to $11.7m ATM placement.

investing.com3 min
JUL 10
$SILOHighAI 9/10

Silo Pharma stock tumbles 22% on dilutive private placement By Investing.com

Silo Pharma (NASDAQ:SILO) shares dropped 22% after the company announced an up to $11.7 million private placement under Nasdaq rules. It plans to issue 619,965 shares plus Series A-3 and A-4 warrants for up to 619,965 shares each at $6.452 per share. Expected gross proceeds are about $4 million upfront, with up to about $7.7 million more if warrants are exercised.

investing.com4 min